Brent Vaughan

Brent Vaughan is CEO, Cognito Therapeutics.


Moving Beyond Traditional Approaches to Alzheimer’s Disease

The recent FDA approval of Biogen’s controversial drug aducanumab is the first drug approved for Alzheimer’s disease in nearly 20 years, and highlights the urgent need for new disease modifying approaches in drug development in this indication.